These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12506182)

  • 1. Dendritic cell-based vaccination in solid cancer.
    Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Schueller G; Zontsich T; Benkoe T; Radelbauer K; Brostjan C; Jakesz R; Gnant M
    J Clin Oncol; 2003 Jan; 21(1):135-42. PubMed ID: 12506182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cell vaccination in medullary thyroid carcinoma.
    Stift A; Sachet M; Yagubian R; Bittermann C; Dubsky P; Brostjan C; Pfragner R; Niederle B; Jakesz R; Gnant M; Friedl J
    Clin Cancer Res; 2004 May; 10(9):2944-53. PubMed ID: 15131029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.
    Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Benkoe T; Brostjan C; Jakesz R; Gnant M
    Int J Oncol; 2003 Mar; 22(3):651-6. PubMed ID: 12579320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma.
    Bachleitner-Hofmann T; Friedl J; Hassler M; Hayden H; Dubsky P; Sachet M; Rieder E; Pfragner R; Brostjan C; Riss S; Niederle B; Gnant M; Stift A
    Oncol Rep; 2009 Jun; 21(6):1585-92. PubMed ID: 19424640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.
    Chang AE; Redman BG; Whitfield JR; Nickoloff BJ; Braun TM; Lee PP; Geiger JD; Mulé JJ
    Clin Cancer Res; 2002 Apr; 8(4):1021-32. PubMed ID: 11948109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
    Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
    Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.
    Geiger JD; Hutchinson RJ; Hohenkirk LF; McKenna EA; Yanik GA; Levine JE; Chang AE; Braun TM; Mulé JJ
    Cancer Res; 2001 Dec; 61(23):8513-9. PubMed ID: 11731436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.
    Babatz J; Röllig C; Oelschlägel U; Zhao S; Ehninger G; Schmitz M; Bornhäuser M
    J Hematother Stem Cell Res; 2003 Oct; 12(5):515-23. PubMed ID: 14594508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
    Avigan DE; Vasir B; George DJ; Oh WK; Atkins MB; McDermott DF; Kantoff PW; Figlin RA; Vasconcelles MJ; Xu Y; Kufe D; Bukowski RM
    J Immunother; 2007 Oct; 30(7):749-61. PubMed ID: 17893567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
    Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
    de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ
    Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.
    Palmer DH; Midgley RS; Mirza N; Torr EE; Ahmed F; Steele JC; Steven NM; Kerr DJ; Young LS; Adams DH
    Hepatology; 2009 Jan; 49(1):124-32. PubMed ID: 18980227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2.
    Nagayama H; Sato K; Morishita M; Uchimaru K; Oyaizu N; Inazawa T; Yamasaki T; Enomoto M; Nakaoka T; Nakamura T; Maekawa T; Yamamoto A; Shimada S; Saida T; Kawakami Y; Asano S; Tani K; Takahashi TA; Yamashita N
    Melanoma Res; 2003 Oct; 13(5):521-30. PubMed ID: 14512794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
    Katano M; Morisaki T; Koga K; Nakamura M; Onishi H; Matsumoto K; Tasaki A; Nakashima H; Akiyoshi T; Nakamura M
    Anticancer Res; 2005; 25(6A):3771-6. PubMed ID: 16302738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy with dendritic cells pulsed by autologous dactinomycin-induced melanoma apoptotic bodies for patients with malignant melanoma.
    Chang JW; Hsieh JJ; Shen YC; Ho E; Chuang CK; Chen YR; Liao SK; Chen JS; Leong SP; Hou MM; Chang NJ; Wang CH
    Melanoma Res; 2009 Oct; 19(5):309-15. PubMed ID: 19750589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
    Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
    Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma.
    Redman BG; Chang AE; Whitfield J; Esper P; Jiang G; Braun T; Roessler B; Mulé JJ
    J Immunother; 2008; 31(6):591-8. PubMed ID: 18528294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study.
    Burgdorf SK; Fischer A; Claesson MH; Kirkin AF; Dzhandzhugazyan KN; Rosenberg J
    J Exp Clin Cancer Res; 2006 Jun; 25(2):201-6. PubMed ID: 16918131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.